Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Novartis ADR representing 1 Ord Shs NVS

Healthcare
Novartis AG is a Switzerland-based pharmaceutical company. The Company develops, manufactures, and markets branded and generic prescription drugs, active pharmaceutical ingredients (APIs), biosimilars and ophthalmic products. The Company uses science and digital technologies for treatments in the disease areas of immunology, dermatology, cancer, ophthalmology, neuroscience, respiratory... see more

Recent & Breaking News (NYSE:NVS)

INVESTIGATION ALERT: The Schall Law Firm Encourages Investors in Novartis AG with Losses of $100,000 to Contact the Firm

Business Wire July 14, 2022

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors Novartis AG - NVS

PR Newswire July 13, 2022

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors Novartis AG - NVS

Newsfile July 11, 2022

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors Novartis AG - NVS

PR Newswire July 5, 2022

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors Novartis AG - NVS

Newsfile June 15, 2022

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors Novartis AG - NVS

PR Newswire June 8, 2022

NOVARTIS ALERT: Bragar Eagel & Squire, P.C. is Investigating Novartis AG on Behalf of Novartis Stockholders and Encourages Investors to Contact the Firm

Business Wire June 2, 2022

NOVARTIS ALERT: Bragar Eagel & Squire, P.C. is Investigating Novartis AG on Behalf of Novartis Stockholders and Encourages Investors to Contact the Firm

Business Wire June 1, 2022

Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Announces Investigation of Novartis AG (NVS) on Behalf of Investors

Business Wire June 1, 2022

INVESTOR ALERT: Law Offices of Howard G. Smith Announces Investigation of Novartis AG (NVS) on Behalf of Investors

Business Wire May 31, 2022

The Law Offices of Frank R. Cruz Announces Investigation of Novartis AG (NVS) on Behalf of Investors

Business Wire May 31, 2022

Voyager Therapeutics Reports Fourth Quarter and Full Year 2021 Financial and Operating Results

GlobeNewswire March 8, 2022

Adaptimmune Announces Appointment of Cintia Piccina as Chief Commercial Officer

GlobeNewswire January 26, 2022

Novartis data highlight efficacy of Piqray® in HR+/HER2- metastatic breast cancer with a PIK3CA driver mutation immediately post-CDK4/6i

PR Newswire December 10, 2021

Novartis presents new Kisqali® data showing longest median overall survival ever reported in HR+/HER2- advanced breast cancer

PR Newswire September 19, 2021

Lp(a) HORIZON achieves 50% enrollment in trial to assess the safety and efficacy of pelacarsen in reducing recurrent cardiovascular events

PR Newswire August 2, 2021

Novartis US Foundation commits $25M to improve health equity by reducing health disparities in the US

PR Newswire September 16, 2020

Yates Class Action Law Encourages Long Term Stockholders of Novartis AG (NYSE: NVS) to Contact The Firm

ACCESSWIRE IA July 7, 2020

NVS Investor Alert: Bronstein, Gewirtz & Grossman, LLC Announces Investigation of Novartis AG and Encourages Investors to Contact the Firm

ACCESSWIRE IA June 29, 2020

EQUITY ALERT: Rosen Law Firm Announces Investigation of Securities Claims Against Novartis AG - NVS

Business Wire June 26, 2020